Premier Research Group has announced the appointment of Dr. Colin Hayward to the position of European Medical Director.
In this position, Dr. Hayward will be responsible for leading and developing the company’s European medical affairs and pharmacovigilance operations, critical components of the company’s global clinical development services offered to the biopharmaceutical industry.
“Dr. Hayward brings medical expertise, clinical knowledge, leadership, and a wealth of experience in key areas important to our customers and will provide an added level of therapeutic insight to Premier’s services,” said Dr. Sue Stansfield, Executive Vice President, Clinical Development.
Dr. Stansfield continued, “He will be a tremendous asset for both employees and customers and is a welcome addition to our strong team in Europe.”
Dr. Hayward is a board certified pharmaceutical physician with 12 years international experience in pharmacovigilance, design and implementation of clinical programs and medical affairs.
Before joining Roche pharmacovigilance and quickly progressing through a series of positions with increasing responsibility to International Medical Leader, Dr Hayward practiced in the UK Health Service in anaesthesia and intensive care.
Most recently Dr Hayward was Director of Prism Ideas Ltd with responsibility for the medical team of this pharmaceutical medicine consultancy.
Dr. Hayward attended the medical schools of Guys & St. Thomas’s Hospitals in London.